secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apellis Pharmaceuticals, Inc. (APLS)
CIK:        0001492422
Form:       8-K
Filed at:   2023-12-01T23:59:59+00:00
Accession:  0001193125-23-286826
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Apellis updates SYFOVRE label to include rare retinal vasculitis risk; rate 0.01% per injection
--------------------------------------------------------------------------------

- Updated USPI Warnings/Precautions and Postmarketing Experience sections to include retinal vasculitis with/without occlusion.
- Estimated rate of retinal vasculitis remains rare at 0.01% per injection, based on over 120,000 injections administered as of Nov 18, 2023.
- Label update pursued in collaboration with the FDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1492422/000119312523286826/0001193125-23-286826-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1492422/000119312523286826/d616555d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-286826

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer